These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16802855)

  • 21. Development of a sensitive method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography-tandem mass spectrometry.
    Gaudette F; Sirhan-Daneau A; St-Onge M; Turgeon J; Michaud V
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jan; 1008():174-180. PubMed ID: 26655109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02).
    Malhotra BK; Matschke K; Wang Q; Bramson C; Salageanu J
    Clin Drug Investig; 2015 Apr; 35(4):267-74. PubMed ID: 25724154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maturation of oxycodone pharmacokinetics in neonates and infants: Oxycodone and its metabolites in plasma and urine.
    Kokki M; Heikkinen M; Välitalo P; Hautajärvi H; Hokkanen J; Pitkänen H; Sankilampi U; Ranta VP; Kokki H
    Br J Clin Pharmacol; 2017 Apr; 83(4):791-800. PubMed ID: 27780305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A crossover pharmacokinetic study of misoprostol by the oral, sublingual and buccal routes.
    Frye LJ; Byrne ME; Winikoff B
    Eur J Contracept Reprod Health Care; 2016 Aug; 21(4):265-8. PubMed ID: 27102981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone.
    Nieminen TH; Hagelberg NM; Saari TI; Pertovaara A; Neuvonen M; Laine K; Neuvonen PJ; Olkkola KT
    Anesthesiology; 2009 Jun; 110(6):1371-8. PubMed ID: 19417618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients.
    Andreassen TN; Klepstad P; Davies A; Bjordal K; Lundström S; Kaasa S; Dale O
    Eur J Clin Pharmacol; 2011 May; 67(5):493-506. PubMed ID: 21140139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort.
    Krishnamurthy RB; Upton RN; Fajumi AO; Lai S; Charlton CS; Ousley RM; Martinez AM; McConnell H; O'Connor SN; Ong J; Macintyre PE; Chapman MJ; Ludbrook GL
    Anaesth Intensive Care; 2012 Mar; 40(2):269-74. PubMed ID: 22417021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of pH on sublingual absorption of oxycodone hydrochloride.
    Al-Ghananeem AM; Malkawi AH; Crooks PA
    AAPS PharmSciTech; 2006 Mar; 7(1):E163-E167. PubMed ID: 28290038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the pharmacokinetics of oxycodone and noroxycodone in male dark agouti and Sprague--Dawley rats: influence of streptozotocin-induced diabetes.
    Huang L; Edwards SR; Smith MT
    Pharm Res; 2005 Sep; 22(9):1489-98. PubMed ID: 16132361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacokinetics of oral oxycodone in patients after total gastric resection.
    Szałek E; Karbownik A; Murawa D; Połom K; Tezyk A; Gracz J; Grabowski T; Grześkowiak E; Biczysko-Murawa A; Murawa P
    Eur Rev Med Pharmacol Sci; 2014 Oct; 18(20):3126-33. PubMed ID: 25392115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measurements of plasma oxycodone, noroxycodone and oxymorphone levels in a patient with bilateral nephrectomy who is undergoing haemodialysis.
    Lee MA; Leng ME; Cooper RM
    Palliat Med; 2005 Apr; 19(3):259-60. PubMed ID: 15920941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous determination of oxycodone and its major metabolite, noroxycodone, in human plasma by high-performance liquid chromatography.
    Cheremina O; Bachmakov I; Neubert A; Brune K; Fromm MF; Hinz B
    Biomed Chromatogr; 2005 Dec; 19(10):777-82. PubMed ID: 15920700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain.
    Hao GT; Zhou HY; Gao HZ; Qu HY; Liang YG; Li YY; Dong RH; Zhang LJ; Wang XF; Liu ZY
    Pharmacol Rep; 2014 Feb; 66(1):153-8. PubMed ID: 24905321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Marked variation in oxycodone pharmacokinetics in infants.
    Pokela ML; Anttila E; Seppälä T; Olkkola KT
    Paediatr Anaesth; 2005 Jul; 15(7):560-5. PubMed ID: 15960639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone.
    Takala A; Kaasalainen V; Seppälä T; Kalso E; Olkkola KT
    Acta Anaesthesiol Scand; 1997 Feb; 41(2):309-12. PubMed ID: 9062618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxycodone pharmacokinetics and fetal exposure after intravenous or epidural administration to the ewe.
    Kinnunen M; Kokki H; Hautajärvi H; Huhta H; Ranta VP; Räsänen J; Voipio HM; Kokki M
    Acta Obstet Gynecol Scand; 2018 Oct; 97(10):1200-1205. PubMed ID: 29772054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prescription opioids. III. Disposition of oxycodone in oral fluid and blood following controlled single-dose administration.
    Cone EJ; DePriest AZ; Heltsley R; Black DL; Mitchell JM; LoDico C; Flegel R
    J Anal Toxicol; 2015 Apr; 39(3):192-202. PubMed ID: 25589778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment.
    Malhotra BK; Schoenhard GL; de Kater AW; Friedmann N
    J Opioid Manag; 2015; 11(2):157-69. PubMed ID: 25901481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.
    Lalovic B; Kharasch E; Hoffer C; Risler L; Liu-Chen LY; Shen DD
    Clin Pharmacol Ther; 2006 May; 79(5):461-79. PubMed ID: 16678548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.